Symptoms of glucocorticoid-induced adrenal insufficiency - a systematic evaluation of clinician- and patient-reported symptoms and their significance for patients’ decisions to take hydrocortisone stress doses
OBJECTIVE: Glucocorticoid-induced adrenal insufficiency (GIAI) is a common, distinct form of adrenal insufficiency, yet its symptom profile remains poorly characterized. We systematically evaluated clinician- and patient-reported symptoms and the significance patients ascribe to them as indicators of a need for hydrocortisone stress doses. DESIGN: Mixed-methods sequential survey and interview study. METHODS: Endocrinologists from Danish tertiary adrenal centres evaluated the 80 symptoms in the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), rated their relevance to GIAI, and suggested additional symptoms. Symptoms with mean relevance score ≥1 ('a little relevant') underwent final expert review before being explored in semi-structured patient interviews. Adult patients with GIAI for >6 months were recruited from endocrine outpatient clinics. Patients described symptom experiences, marked symptoms they recognized on the expert-generated list, and rated their significance for deciding to administer hydrocortisone stress doses. New symptoms were incorporated into subsequent interview rounds, continuing until symptom saturation. RESULTS: Eleven endocrinologists identified 17 relevant symptoms; three were excluded during final expert review, leaving 14 symptoms for patient evaluation. Thirty patients (median [IQR] GIAI duration 5.0 [3.2-9.6] years) participated and identified 14 additional symptoms. The most frequently reported symptoms were fatigue, feeling unwell, lethargy, difficulty concentrating, and nausea (all ≥60%). Symptoms with the highest significance ratings were vomiting, nausea, dizziness, hot flashes, fatigue, and feeling unwell (all >3, 'moderately important'). CONCLUSIONS: We identified 28 GIAI-relevant symptoms and characterized their frequency and patient-reported importance in guiding real-world dosing decisions, providing a patient-centred basis for symptom monitoring in GIAI.
Authors
- Hajir Al-Jorani (ORCID: https://orcid.org/0000-0002-4938-3327)
- Simon Bøggild Hansen (ORCID: https://orcid.org/0000-0002-3699-6159)
- Randi Tei (ORCID: https://orcid.org/0000-0002-0658-011X)
- Anja Fenger Dreyer (ORCID: https://orcid.org/0000-0001-8079-213X)
- Jakob Bue Bjørner (ORCID: https://orcid.org/0000-0001-7033-8224)
- Marianne Klose (ORCID: https://orcid.org/0000-0001-6075-0821)
- Victor Brun Boesen (ORCID: https://orcid.org/0000-0003-2792-6738)
- Stina Willemoes Borresen (ORCID: https://orcid.org/0000-0002-3939-3388)
- Ulla Feldt‐Rasmussen (ORCID: https://orcid.org/0000-0002-5903-3355)
- Marie Louise Lund Bjergstrøm
Institutions
- University of Copenhagen (DK)
- University of Southern Denmark (DK)
- Aarhus University (DK)
- Odense University Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- University College Copenhagen (DK)
- National Research Centre for the Working Environment (DK)
Publication Details
- Journal
- European Journal of Endocrinology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1093/ejendo/lvag205
- Primary Topic
- Adrenal Hormones and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00